The results remained unchanged; all endpoints that were highly significant in favour of liraglutide in the primary efficacy analysis remained so, with a greater reduction in HbA1c concentrations of 12.1 mmol/mol (1.1%), compared with participants in the placebo group.
← all excerpts
Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).
1
—
—